secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aquestive Therapeutics, Inc. (AQST)
CIK:        0001398733
Form:       8-K
Filed at:   2024-07-25T23:59:59+00:00
Accession:  0001628280-24-032917
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aquestive reports positive topline PK data for Anaphylm self-administration study
--------------------------------------------------------------------------------

- Self-administration PK study met primary endpoints; PK comparable whether administered by subjects or HCPs.
- Median Tmax of 15 minutes for Anaphylm self-admin & HCP-admin vs 50 minutes for Adrenalin IM injection in 36 healthy adults.
- Remaining supportive OAS challenge study underway, expected completion late Q3 or early Q4 2024.
- Company maintains NDA filing guidance late Q4 2024/early Q1 2025 and product launch by end 2025 or Q1 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1398733/000162828024032917/0001628280-24-032917-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1398733/000162828024032917/aqst-20240725.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-032917

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer